T1G3 bladder cancer--indications for early cystectomy

Area of Science:

• Urology
• Oncology

Background:

• Transitional Cell Carcinoma (TCC) of the bladder, specifically T1G3 stage, presents a clinical challenge.
• Early detection and appropriate treatment are crucial for improving patient outcomes.

Purpose of the Study:

• To evaluate the outcomes of early radical cystectomy in patients diagnosed with T1G3 Transitional Cell Carcinoma (TCC) of the bladder.
• To identify patient subgroups that benefit most from radical cystectomy versus conservative management.

Main Methods:

• A retrospective review of 30 patients with clinical stage T1G3 TCC bladder who underwent early radical cystectomy over a 10-year period.
• Patients were categorized based on tumor characteristics: single tumor without Carcinoma In-Situ (CIS) versus multiple tumors with or without CIS.
• Disease-specific survival was analyzed using Kaplan-Meier estimates.

Main Results:

• Upstaging after cystectomy occurred in 55% of patients with multiple tumors/CIS (Group B) compared to 6% in single tumors without CIS (Group A) (p=0.009).
• Complete tumor eradication (pT0) was observed in 53% of Group A patients versus 0% in Group B (p=0.0017).
• Five-year cancer-specific survival rates were 92% for Group A and 82% for Group B.

Conclusions:

• Patients with multiple T1G3 tumors, or single tumors with CIS, have a 55% incidence of already being muscle-invasive at diagnosis.
• Early radical cystectomy is strongly advocated for these high-risk patients.
• A conservative, bladder-preserving approach with immuno-chemotherapy and surveillance is justified for single T1G3 tumors without CIS.